The strength of our study is that it comprehensively demonstrated that anti-TNF treatment did not influence the paradoxical development of psoriasis and the types of anti-TNF agents were not related to the risk of psoriasis in IBD patients. This evidence concerns the gene TNF and inflammatory bowel disease.